Board member in Diamyd Medical buys shares from main owner
Board member Mark Atkinson has bought 10,000 Diamyd Medical B-shares at SEK 30.60 per share from Board member and main owner Anders Essen-Möller. Mark Atkinson’s holdings in Diamyd Medical amounts after the transaction to 16,750 B-shares. “I am happy about the development in Diamyd Medical and I am proud to increase my investment in the company also as a shareholder,” says Professor Mark Atkinson. About Diamyd MedicalDiamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin